PT‑141 (bremelanotide) 10 mg/mL (5 mL vial) is a compounded melanocortin peptide designed to act centrally in the brain, where it modulates receptors involved in sexual desire and arousal rather than directly affecting blood flow like PDE5 inhibitors. By targeting melanocortin‑4 and related receptors, PT‑141 can help eligible men and women address low libido and situational sexual dysfunction as part of a broader, medically supervised sexual wellness plan.


